how AHCC works by impacting specific immune system cells. More studies will be conducted to further investigate the effects of AHCC," said Naoyoshi Terakawa, M.D., Department of Surgery, Kansai Medical University.
In addition to this study, research completed at other institutions with AHCC has shown that it activates important immune white blood cells including macrophages, Natural Killer (NK) cells and Lymphokine-Activated Killer (LAK) cells. AHCC also induces the production of cytokines that serve as chemical messengers between cells. AHCC has been the subject of over 80 research studies worldwide including studies completed at Harvard University's Faulkner Hospital, Yale University and Columbia University Medical Center.
What is AHCC (Active Hexose Correlated Compound)?
AHCC is derived from the hybridization of several subspecies of medicinal mushroom, cultivated in Japan and then produced from a unique manufacturing process. AHCC is the leading immune-enhancing supplement in Japan and is utilized by over 700 hospitals and healthcare facilities worldwide as a standard preventative supplement for incoming patients to help reduce the risk of hospital infections as well as supporting the body's fight against the formation of abnormal cells.*
AHCC is manufactured by Amino Up Chemical Company in Sapporo, Japan and is distributed in the United States by Maypro Industries. Maypro sells AHCC to a number of leading supplement companies including Quality of Life Laboratories, a subsidiary of Maypro.
The AHCC Research Association was founded in 1986 to promote further study. Each year since 1994, over 300 medical doctors and researchers have gathered in Sapporo, Japan for the AHCC Research Association Symposium to share and discuss the latest developments.
To learn more about AHCC, visit the AHCC Research Association Web site at
Page: 1 2 3 Related medicine technology :1
|SOURCE AHCC Research Association|
Copyright©2009 PR Newswire.
All rights reserved
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2
. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer3
. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain4
. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma5
. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor6
. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-7967
. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD8
. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study9
. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression10
. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus11
. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes